Submit Manuscript  

Article Details


Icariin Stimulates hFOB 1.19 Osteoblast Proliferation and Differentiation via OPG/RANKL Mediated by the Estrogen Receptor

[ Vol. 22 , Issue. 1 ]

Author(s):

Lin-Jun Sun, Chong Li, Xiang-hao Wen, Lu Guo, Zi-Fen Guo, Lan-qing Liao and Yu Guo*   Pages 168 - 175 ( 8 )

Abstract:


Background: Icariin (ICA), one of the main effective components isolated from the traditional Chinese herb Epimedium brevicornu Maxim., has been reported to possess extensive pharmacological actions, including enhanced sexual function, immune regulation, anti-inflammation, and antiosteoporosis.

Methods: Our study was designed to investigate the effect of ICA on cell proliferation and differentiation and the molecular mechanism of OPG/RANKL mediated by the Estrogen Receptor (ER) in hFOB1.19 human osteoblast cells.

Results: The experimental results show that ICA can stimulate cell proliferation and increase the activity of Alkaline Phosphatase (ALP), Osteocalcin (BGP) and I Collagen (Col I) and a number of calcified nodules. Furthermore, the mRNA and protein expression of OPG and RANKL and the OPG/ RANKL mRNA and protein expression ratios were upregulated by ICA. The above-mentioned results indicated that the optimal concentration of ICA for stimulating osteogenesis was 50ng/mL. Subsequent mechanistic studies comparing 50ng/mL ICA with an estrogen receptor antagonist demonstrated that the effect of the upregulated expression is connected with the estrogen receptor. In conclusion, ICA can regulate bone formation by promoting cell proliferation and differentiation and upregulating the OPG/RANKL expression ratio by the ER in hFOB1.19 human osteoblast cells.

Keywords:

Icariin, hFOB1.19, osteoblast, proliferation, differentiation, OPG/RANKL.

Affiliation:

Nanhua Affiliated Hospital of University of South China, Hengyang, Hu’nan, 421001, Nanhua Affiliated Hospital of University of South China, Hengyang, Hu’nan, 421001, Nanhua Affiliated Hospital of University of South China, Hengyang, Hu’nan, 421001, Nanhua Affiliated Hospital of University of South China, Hengyang, Hu’nan, 421001, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hu’nan, 421001, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hu’nan, 421001, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hu’nan, 421001

Graphical Abstract:



Read Full-Text article